Tuberculosis (TB) in young infants (< 3 months of age), often referred to as perinatal TB, is
underdiagnosed, leading to severe morbidity and high mortality. Perinatal TB includes both …

Infants of mothers treated for tuberculosis might be exposed to drugs via breast milk. The
existing information on the exposure of breastfed infants lacks a critical review of the …

BACKGROUND: We examined whether the updated WHO weight-band dosing
recommendations and fixed-dose combination tablets for the treatment of TB in children …

Background The current World Health Organization (WHO) pediatric tuberculosis dosing
guidelines lead to suboptimal drug exposures. Identifying factors altering the exposure of …

Pyrazinamide is a first-line tuberculosis drug with potent sterilizing activity. Variability in drug
exposure may potentially translate into suboptimal treatment responses. This systematic …

Background We evaluated dolutegravir pharmacokinetics in infants with human
immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based …

Background Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-
/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the …

The spread of tuberculosis (TB), especially multidrug-resistant TB and extensively drug-
resistant TB, has strongly motivated the research and development of new anti-TB drugs …

Background Pharmacokinetic data of rifampin, when used for tuberculosis preventive
treatment (TPT) are not available. We aimed to describe the pharmacokinetics of rifampin …

At the 2018 United Nations High-Level Meeting on TB, it was decided that the gap between
TB incidence and children receiving treatment should be reduced significantly. Although the …